Sun Pharma approves INR 100.0 billion plan: Sun Pharma stock sits 13.79 percent below high

Published on 10/15/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-quarter fiscal 2027 revenue rose 4.71 percent to INR 153.00 billion. Sun Pharma stock is valued at INR 4.2 trillion on October 15, 2026.

Funding and operating scale

Sun Pharma approved a debt proposal of INR 100.0 billion at its October 12, 2026 board meeting.
First-quarter fiscal 2027 revenue reached INR 153.0 billion after a 4.71 percent quarter-on-quarter increase.
Sun Pharma stock had a market value of INR 4.2 trillion as of October 15, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (ISIN INE044A01036) approved a plan to raise up to INR 100.0 billion through non-convertible debentures at its October 12, 2026 board meeting, according to Business Standard. The proposal gives the company another funding channel as it expands its specialty medicines portfolio.

Three milestones shape the story

The recent chronology is clear. On June 30, 2026, first-quarter fiscal 2027 revenue reached INR 153.0 billion and net profit stood at INR 29.11 billion, according to StockFin. On October 6, 2026, Sun Pharma announced a USD 2.5 million dermatology professorship at Mount Sinai through Yahoo Finance. The October 12, 2026 board decision on INR 100.0 billion of debentures is the latest event.

What does the funding plan change?

The proposed issue is material against the balance sheet. StockFin lists borrowings of INR 40.82 billion as of March 2026, so the maximum debenture program is 145.00 percent larger than that reported borrowing base. The comparison points to financing capacity rather than a completed cash inflow, because the Business Standard report says issuance and allotment disclosures will follow at a later stage.

Next date for investors

StockFin lists October 30, 2026 as the next board meeting date for consideration of unaudited standalone and consolidated financial results. That date is the next scheduled corporate checkpoint in the cited filing calendar.

Stock stays below its yearly high

Sun Pharma was last at INR 1,764.60 on the NSE on October 15, 2026 at 2:33 p.m. IST, while the 52-week range was INR 1,583.70 to INR 2,046.90. The quote stood 13.79 percent below the upper end of that range, keeping the funding decision and first-quarter operating figures central to the stock's near-term reading.